Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Parental Management of Young Children's Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes

Interventions: Behavioral: Parental Support
Behavioral: Diabetes Education

First Posted Date: 2009-02-19

Last Posted Date: 2018-03-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 134

Registration Number: NCT00847327

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

Reduced Carbohydrate Versus Fat in Obese Subjects

Phase 2

Completed

Conditions: Obesity

Interventions: Other: Reduced fat diet
Other: Reduced carbohydrate diet
Device: fMRI
Device: PET

First Posted Date: 2009-02-18

Last Posted Date: 2021-04-15

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 43

Registration Number: NCT00846040

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Phase 3

Active, not recruiting

Conditions: Anemia
Chronic Myelomonocytic Leukemia
De Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome

Interventions: Procedure: Bone Marrow Biopsy
Biological: Epoetin Alfa
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide

First Posted Date: 2009-02-13

Last Posted Date: 2025-06-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 247

Registration Number: NCT00843882

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States

and more 502 locations

Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

Phase 2

Completed

Conditions: Precancerous Condition

Interventions: Other: placebo
Drug: sulindac
Other: laboratory biomarker analysis

First Posted Date: 2009-02-11

Last Posted Date: 2017-12-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00841204

Locations: 🇺🇸
University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Phase 2

Terminated

Conditions: Diabetes Mellitus Type 1
Autoimmune Diabetes

Interventions: Drug: Insulin
Drug: Lansoprazole
Drug: Sitagliptin
Biological: Diamyd
Drug: GAD65 (Diamyd)

First Posted Date: 2009-02-05

Last Posted Date: 2013-01-03

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 7

Registration Number: NCT00837759

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

Early Phase 1

Terminated

Conditions: Mucinous Adenocarcinoma of the Rectum
Stage IV Colon Cancer
Liver Metastases
Mucinous Adenocarcinoma of the Colon
Recurrent Colon Cancer
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Colon
Signet Ring Adenocarcinoma of the Rectum
Stage IV Rectal Cancer

Interventions: Procedure: therapeutic conventional surgery
Biological: cetuximab
Drug: dasatinib
Other: laboratory biomarker analysis

First Posted Date: 2009-02-04

Last Posted Date: 2014-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT00835679

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Phase 2

Completed

Conditions: Adult Rhabdomyosarcoma
Adult Synovial Sarcoma
Recurrent Adrenocortical Carcinoma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Retinoblastoma
Recurrent Childhood Liver Cancer
Recurrent Osteosarcoma
Childhood Hepatoblastoma
Childhood Synovial Sarcoma

Interventions: Biological: cixutumumab
Other: laboratory biomarker analysis

First Posted Date: 2009-01-29

Last Posted Date: 2015-03-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 116

Registration Number: NCT00831844

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Southern California Permanente Medical Group, Downey, California, United States

and more 102 locations

Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer

Phase 2

Completed

Conditions: Adenomatous Polyp
Colorectal Carcinoma

Interventions: Drug: macrogol 3350-based oral osmotic laxative
Other: Placebo
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-01-26

Last Posted Date: 2017-04-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 87

Registration Number: NCT00828984

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Extensive Stage Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer

Interventions: Biological: ziv-aflibercept
Drug: topotecan hydrochloride

First Posted Date: 2009-01-23

Last Posted Date: 2017-08-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 189

Registration Number: NCT00828139

Locations: 🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸
Providence Hospital, Mobile, Alabama, United States
🇺🇸
Arizona Cancer Center at UMC Orange Grove, Tucson, Arizona, United States

and more 254 locations

Long-term Follow-up of HALT-C Sustained Virological Responders

Completed

Conditions: Hepatitis C
Ascites
Hepatocellular Carcinoma
Variceal Hemorrhage
Death

First Posted Date: 2009-01-21

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 140

Registration Number: NCT00825877

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy